CN118451091A - 用于靶向细胞表面受体的可裂解放射性配体及其用途 - Google Patents

用于靶向细胞表面受体的可裂解放射性配体及其用途 Download PDF

Info

Publication number
CN118451091A
CN118451091A CN202280078538.7A CN202280078538A CN118451091A CN 118451091 A CN118451091 A CN 118451091A CN 202280078538 A CN202280078538 A CN 202280078538A CN 118451091 A CN118451091 A CN 118451091A
Authority
CN
China
Prior art keywords
alkylene
group
compound
cleavable
cleavable linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280078538.7A
Other languages
English (en)
Chinese (zh)
Inventor
刘发
艾拉·达韦士
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fulian Technology Hong Kong Ltd
Original Assignee
Fulian Technology Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fulian Technology Hong Kong Ltd filed Critical Fulian Technology Hong Kong Ltd
Publication of CN118451091A publication Critical patent/CN118451091A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280078538.7A 2021-11-26 2022-11-23 用于靶向细胞表面受体的可裂解放射性配体及其用途 Pending CN118451091A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283361P 2021-11-26 2021-11-26
US63/283,361 2021-11-26
PCT/US2022/050952 WO2023097038A1 (en) 2021-11-26 2022-11-23 Cleavable radioligands for targeting cell surface receptors and uses thereof

Publications (1)

Publication Number Publication Date
CN118451091A true CN118451091A (zh) 2024-08-06

Family

ID=86540347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280078538.7A Pending CN118451091A (zh) 2021-11-26 2022-11-23 用于靶向细胞表面受体的可裂解放射性配体及其用途

Country Status (9)

Country Link
US (2) US12214059B2 (enExample)
EP (1) EP4436979A4 (enExample)
JP (1) JP2024542592A (enExample)
KR (1) KR20240121775A (enExample)
CN (1) CN118451091A (enExample)
CA (1) CA3238734A1 (enExample)
CL (1) CL2024001560A1 (enExample)
MX (1) MX2024005950A (enExample)
WO (1) WO2023097038A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EP4436979A4 (en) 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
EP4719486A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Conjugates and uses thereof
EP4719498A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Radioligands for targeting cell surface receptors and uses thereof
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
CN118240015B (zh) * 2024-03-21 2025-03-21 中国科学院近代物理研究所 一种针对脑胶质瘤的靶向多肽及放射性示踪剂
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
WO2026080432A1 (en) * 2024-10-07 2026-04-16 Beth Israel Deaconess Medical Center, Inc. Dimeric p-selectin inhibitors and uses thereof
CN121991166A (zh) * 2024-11-05 2026-05-08 成都纽瑞特医疗科技股份有限公司 放射性配体化合物及其用途
WO2026119233A1 (en) * 2024-12-04 2026-06-11 Full-Life Technologies Uk Limited Conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US8575123B2 (en) * 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
ES2743482T3 (es) * 2014-05-06 2020-02-19 Univ Johns Hopkins Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
AU2018352731B2 (en) 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
WO2019165200A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
KR102156385B1 (ko) 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
WO2019246311A1 (en) 2018-06-19 2019-12-26 Lumiphore, Inc. Macrocycle conjugates
ES3038393T3 (en) * 2018-08-09 2025-10-13 Hoffmann La Roche Cleavable linker for peptide synthesis
US20200078478A1 (en) 2018-09-10 2020-03-12 Ming-Hsin Li Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2021163498A1 (en) 2020-02-14 2021-08-19 Northwestern University Retrograde neuronal tracers detectable by fluorescence and other imaging methods
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物
JP7894086B2 (ja) 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
EP4436979A4 (en) 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses

Also Published As

Publication number Publication date
CL2024001560A1 (es) 2025-03-28
US12214059B2 (en) 2025-02-04
EP4436979A1 (en) 2024-10-02
MX2024005950A (es) 2024-08-06
AU2022397307A1 (en) 2024-06-06
US20240382630A1 (en) 2024-11-21
JP2024542592A (ja) 2024-11-15
EP4436979A4 (en) 2026-06-10
KR20240121775A (ko) 2024-08-09
WO2023097038A1 (en) 2023-06-01
US20250099632A1 (en) 2025-03-27
US12673122B2 (en) 2026-07-07
CA3238734A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US12214059B2 (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
US11766414B2 (en) Compositions, delivery systems, and methods useful in tumor therapy
JP5308829B2 (ja) 癌の画像化および処置
US7226577B2 (en) Gastrin releasing peptide compounds
EP2790732B1 (en) Clicked somatostatin conjugated analogs for biological applications
EP2100900A1 (en) Bombesin analog peptide antagonist conjugates
US11505525B2 (en) Branched discrete PEG constructs
US12145926B2 (en) Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2024245421A1 (en) Radioligands for targeting cell surface receptors and uses thereof
WO2024245407A1 (en) Conjugates and uses thereof
WO2025116046A1 (ja) ペプチド及び当該ペプチドを含むコンジュゲート
JP2023506297A (ja) 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド
WO2024083224A1 (en) Dual receptor targeting radioligands and uses thereof related applications
HK40111230A (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
CA3258869A1 (en) ZWITTERIONIC COMPOUNDS AND THEIR USES
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
WO2025113628A1 (en) Sstr receptor targeting radio compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111230

Country of ref document: HK